Drugs & Pharmaceuticals

Antiviral drug development for COVID-19 took a back seat to vaccines during the brief time – when we thought that ending the pandemic was simply a matter of getting enough needles in enough arms. But the virus had other ideas: variants. Now it's looking like we may need a drug to complement the vaccines. Three are in development. Here's a look at Pfizer's PF-07321332. It should work, but don't hold me to that.
Some experts have argued that America's expensive, inefficient health care system is to blame for our intense vaccine hesitancy. While this is a plausible explanation, it misses the key problem—the politicization of medicine, along with almost everything else in our culture.
Remdesivir, an antiviral drug with the potential to treat COVID, has been largely ignored since its "introduction" to the world at the beginning of COVID. It just didn't seem to work very well. But data from a Phase 3 trial by Gilead was a surprise. The drug, when given to COVID patients in a non-hospital setting, did a very good job of keeping them out of the hospital. Here's a summary of the clinical data.
A group at Sloan Kettering is proposing the use of certain types of chemotherapy drugs to treat SARS-CoV-2 infection. One cannot help thinking of the old adage about what everything looks like when you only have a hammer.
I get it. People are sick and tired of COVID and endlessly cranky about having to deal with the changing facts and rules. Some of this discontent is expressed as dissatisfaction with the vaccines. While this frustration may be understandable it is not warranted. The vaccines are nothing short of a medical miracle. Don't shoot the messenger RNA. Blame the virus.
Mechanical ventilation is an imperfect method of supplying oxygen to patients who are hypoxic, but there aren't satisfactory alternatives. A recent study by a Japanese group has shown that a "butt breathing tube," probably not as delightful as it sounds, can supply oxygen to mice, rats, and pigs that were exposed to hypoxic conditions. Can this work in people?
Dr. Schwarcz, the Director of McGill University's Office for Science and Society, and a long-time friend of ACSH has devoted one of his famous YouTube videos to ivermectin, including its history and evidence of efficacy (or the lack of) against COVID-19.
I just got my COVID booster! I'm quite happy about this but it was a rather strange experience. Here's why.
Anti-vaccine group Children's Health Defense is abusing a new study of COVID-19 breakthrough cases to badmouth very effective shots.
Almost all doctors and nurses in the US have been fully immunized. A survey asked them about getting a booster and the answer was an enthusiastic "yes." But doctors and nurses have somewhat different responses, probably due to a difference in risk tolerance.
I've been following (and writing about) Antibe Therapeutics' otenaproxesul, an atypical NSAID without the GI toxicity of Aleve or Advil, since early 2020. It's been nothing but good news. Until now. Otenaproxesul caused a substantial jump in liver enzymes in some clinical trial participants. Can the company overcome this? Wall Street sure doesn't think so.
New data have been published on drug overdose deaths in 2020. Although you won't find it anywhere obvious, prescription opioid analgesics remain only a minor (and stable) contributor to the record 93,000 people who died from drug overdoses last year.